This study aimed to use the LiquidBiopsy system and immunofluorescence to measure human epidermal growth factor receptor 2 in circulating breast cancer cells. Seventy-one patients with breast cancer and 107 control provided blood samples. The results indicated that the LiquidBiopsy system may be useful for detecting human epidermal growth factor receptor 2 expression levels on CTC as it was positively correlated with pathologic examination. Background: Most previous studies of circulating tumor cells (CTCs) are based on the CellSearch platform, but CellSearch has a number of limitations. This study aimed to use the LiquidBiopsy system and immunofluorescence to test the human epidermal growth factor receptor 2 (HER2) status of CTCs in patients with breast cancer. Materials and Methods: The LiquidBiopsy system was used to detect HER2-positive (HER2 þ ) cells in whole blood by microfluidic immunomagnetic bead screening and immunofluorescence assay, according to the manufacturer;s instructions. HER2 expression on CTCs was assessed using the Ariol system, calibrated through spiking experiments of 100 cells (BT474, SKBR3, A431, and MDA-MB-231) and 2.5 Â 10 7 white blood cells/mL from healthy donors. Seventyone patients with breast cancer and 107 non-cancer donors consented to provide blood. Results: Based on breast cancer cell lines experiments, HER2 þ CTCs were defined as CTCs with HER2 immunofluorescence intensity ! 3.5 times higher than the CD45 immunofluorescence intensity (100% sensitivity and 99.9% specificity). Among the 71 patients with breast cancer, 31 (43.7%) had HER2 þ tumor. Among the HER2 þ patients, 41.9% (13/31) were found to be HER2 þ based on CTC ! 1, and 25.8% (8/31) were positive based on CTC ! 3. In HER2-negative patients by pathologic examination, 1 (2.5%) patient was found to have ! 3 HER2 þ CTCs, whereas 15 (37.5%) patients had ! 1 HER2 þ CTC. HER2 þ CTCs were detected at all stages, even in early breast cancer, but the detection rate was higher in metastatic breast cancer. Conclusion: This proof-of-concept study strongly suggests that HER2 þ CTCs can be detected using the LiquidBiopsy system.
Introduction
Circulating tumor cells (CTCs) are cancer cells that have invaded blood vessels or lymphatics and are carried around the body by the blood. 1 CTCs constitute potential seeds for metastasis because they can reach and implant into distant organs. 2 The clinical importance of CTCs was highlighted in the 1990s with the demonstration of the presence of CTCs early in the disease course. 3 
Subsequent research demonstrated the pivotal role of CTCs in the metastatic
The clinical use of CTCs is not limited to simply counting the cells. Indeed, the use of molecular tests on CTCs is now possible, and this represents the most important and practical application for individualized medicine. Taking breast cancer as an example, patients with human epidermal growth factor receptor 2-positive (HER2 þ ) CTCs could, possibly, benefit from trastuzumab-based therapies, despite a biopsy suggesting a HER2-negative (HER2 À ) primary tumor, because a biopsy and sections from a surgical specimen can miss aggressive HER2 þ foci arising from specific HER2 þ clones. 11, 12 Nevertheless, there are still some limitations in CTC-HER2 detection. First, the different methods of detection (immunofluorescence, immunohistochemistry, in situ hybridization) have different sensitivity values. 13, 14 Second, there is no consensus about the cutoff value for diagnosis and prognosis. [15] [16] [17] Finally, most studies are based on the CellSearch platform because it is the only United States Food and Drug Administrationapproved platform currently, but the CellSearch platform has been shown to have a number of limitations. Indeed, the CellSearch platform is based on the restricted phenotypic definition of a CTCs (cells of epithelial origin expressing cytokeratin but not CD45) and so excludes many classes of informative cells because the system only allows for the detection of CK þ CD45 À cells and does not allow customization for the detection of other cellular characteristics, such as the expression of HER2, estrogen receptor, and progesterone receptor. [18] [19] [20] The present study is based on the LiquidBiopsy system (Cynvenio LLC, Westlake Village, CA), which is a platform that purifies CTCs from whole blood with sufficient purity for direct molecular analysis. The present study aimed to use the LiquidBiopsy system and immunofluorescence to test the HER2 status in CTCs in patients with breast cancer. The results could provide an innovative way to determine the HER2 status in patients with breast cancer.
Material and Methods

CTC Capture Method Using the LiquidBiopsy System
The LiquidBiopsy system focuses on the capture and molecular analysis of CTCs, including cells undergoing epithelial mesenchymal transition. The HER2 þ cells in whole blood were quantitatively detected by microfluidic immunomagnetic bead screening and immunofluorescence assay, according to the manufacturer's instructions. First, biotin-labeled capture antibodies (including HER2-biotin, Epcam-biotin, and other capture antibodies), fluorescence-labeled HER2 antibody, and streptavidin-labeled magnetic beads were added to the sample to obtain complexes made of the magnetic bead, capture antibody, HER2 þ cell, and HER2 detection antibody. In addition, fluorescence-labeled CD45 antibody was added to detect leukocytes. Nuclei staining was used to indicate the intact cells. 
HER2 Protein Expression in Cell Lines
HER2 þ CTC Detection
Peripheral blood samples (4 mL) were collected and stabilized with fixative for 24 to 96 hours, and then lysed using lysis buffer. The biotinylated epithelial mesenchymal transition cocktail and streptavidin beads were used for CTC capture. Labeled CTCs were stained with anti-HER2 monoclonal antibodies (HER2-if488), and WBCs were stained with anti-CD45 monoclonal antibodies (CD45-APC). The identification and counting of CTCs were performed using the Ariol DM6000B system (Leica Microsystems). The HER2 þ CTCs were defined as nucleated cells lacking CD45
and expressing HER2. HER2 expression on CTCs using the Ariol system was calibrated through spiking experiments of 100 cells (BT474, SKBR3, A431, and MDA-MB-231) and 2. Seventy-one patients with breast cancer and 107 non-cancer donors consented to provide blood. All donors were from the Zhuhai Maternity and Child Care Hospital. The study was approved by the medical ethics committee for Zhuhai Maternity and Child Care Hospital. The inclusion criteria were: (1) 18 to 75 years of age; and (2) stage III/IV breast cancer based on primary tumor pathology. The exclusion criteria were: (1) another primary cancer; or (2) any serious comorbidity such as hepatitis or AIDS.
Some patients had received various treatments prior to blood sampling. The pathologic diagnosis of HER2 þ breast cancer was made on the primary tumor.
Statistical Analysis
Categorical variables were presented as frequencies and analyzed using the c 2 test. Continuous variables were presented as medians (range) and analyzed using the Mann-Whitney test. The Pearson correlation test was used to assess the correlations between continuous variables. The receiver operating characteristic curve analysis was used to calculate the cutoff of HER2 staining. All statistical analyses were performed using SPSS 22 (IBM, Armonk, NY) and GraphPad Prism 7 (GraphPad Software Inc, San Diego, CA). Table 1 and Figure 1 present the HER2/CD45 fluorescence intensity ratio of the 5 breast cancer cell lines. As expected, the SKBR3 and BT474 cell lines (HER2 þ ) showed high intensity for HER2/CD45, whereas the HER2 À cell lines and WBCs showed a low intensity. Figure 2 shows the HER2/CD45 fluorescence intensity ratios obtained using the LiquidBiopsy system in the 5 breast cancer cell lines. Using a cutoff value of 3.5 for the HER2/CD45 ratio led to a Youden index of 0.9987, with 100% sensitivity and 99.9% specificity (P < .0001). Figure 3 presents representative images of the CTCs tested for HER2 using the LiquidBiopsy system. Supplemental Table 1 (in the online version) provides the sensitivity and specificity for different cutoff points. Using a cutoff of ! 1 cell/4 ml provides higher sensitivity (41.9%), whereas using ! 3 cells/4 ml provides higher specificity (97.5%).
Results
HER2 Staining of CTCs
CTC HER2 Status in Patients With Breast Cancer
Discussion
Many previous studies of CTCs are based on the CellSearch platform, but CellSearch has a number of limitations, and it does not allow molecular analysis of CTCs. [18] [19] [20] Therefore, the present study aimed to use the LiquidBiopsy system and immunofluorescence to test the HER2 status of CTCs of patients with breast cancer. The results suggest that HER2 þ CTCs detected by the LiquidBiopsy system are associated with the HER2 status of breast cancer by pathologic examination. The cell lines experiments showed high sensitivity (100%) and specificity (99.9%) using a HER2/CD45 fluorescence ratio of 3.5. The present study showed that the LiquidBiopsy system is able to capture breast cancer cells that were spiked among large numbers of WBCs. Based on these experiments, HER2
þ CTCs were defined as CTCs with HER2 immunofluorescence intensity that was ! 3.5 times higher than the CD45 immunofluorescence intensity (100% sensitivity and 99.9% specificity). In addition, the system was able to detect HER2 þ CTCs in patients with early breast cancer who had not received targeted therapy. This is supported by previous studies that also showed the presence of CTCs in patients with early breast cancer, albeit using different methods of detection. [22] [23] [24] [25] [26] Nevertheless, the frequency of CTCs was higher in patients with metastatic breast cancer, which is to be expected because cancer cells from the original clone that caused the metastasis probably had features favoring their spread throughout the body. 4 When we take HER2 þ CTC counts ! 3 as a "strong" HER2 status, significant differences could be found between specimens positive or negative for HER2, providing a possible marker for metastasis.
Of the 71 patients, only 12 had not received any treatment for breast cancer before the study, and the other 59 had been treated with a variety of treatments but no targeted therapy. There was no significant difference in the CTC counts between patients with or without past treatments and this was probably owing to the patients' past treatment not effectively controlling tumor growth. This may also lead to a similar HER2 þ CTC count between the 2 groups of patients. Subsequent studies should explore the difference in HER2 þ CTC count according to a history of HER2-targeted therapy.
Among the 71 patients with breast cancer, 31 (43.7%) had an HER2 þ tumor. Among the HER2 þ patients, 41.9% (13/31) were found to be HER2 þ based on CTC ! 1, and 25.8% (8/31) were positive based on CTC ! 3. This is in agreement with previous studies performed using the CellSearch platform, which showed that 30% to 40% of patients with HER2 þ tumor at pathologic examination also had HER2 Although there is not enough evidence to explain the meaning of small numbers of CTCs in cancer treatments, it is worth studying the clinical value of those low counts in a future study. Taken together, these results highlight that pathologic examination might miss some foci of more aggressive disease and that irrespective of the tumor's characteristics, the CTCs are responsible for the metastatic spread, and their characteristics should be taken first into account for patient management. This also highlights the heterogeneous nature of tumors. Indeed, a tumor may arise from different clones leading to tumor areas with different biological characteristics and aggressiveness. In addition, HER2
À breast cancer cells may spontaneously transform into HER2 þ CTCs. 29 The cells responsible for metastatic spread and disease progression should be regarded as the most dangerous ones, and the treatments should be based on those cells. Nevertheless, in the pre-trastuzumab era, it has been shown that HER2 þ CTCs in patients with stage I to III breast cancer were associated with a poor prognosis. 26 On the other hand, another study showed that discrepancies in HER2 and estrogen receptor statuses between the primary tumor and CTCs had no impact on the prognosis of metastatic breast cancer. 30 Clinical studies are still necessary to prove this point.
The present study is not without limitations. Indeed, the study population was small and heterogeneous, preventing any immediate clinical application of the results. In addition, no comparison was made with other methods for detecting CTCs, such as the CellSearch system. The present study was a proof-of-concept study for the use of the LiquidBiopsy system for the detection of HER2 þ CTCs in patients with breast cancer. At this step, our results cannot be used to determine clinically relevant cutoff points. Additional studies are necessary to determine the prognostic significance of CTCs detected using the LiquidBiopsy system. Nevertheless, the present study indicates that the LiquidBiopsy system can be used to determine molecular characteristics of CTCs. Future studies could examine other characteristics of breast cancer cells such as estrogen receptors, progesterone receptor, and Ki67. This feature of the LiquidBiopsy system could outperform the CellSearch system for individualized medicine because the CellSearch system counts CTCs based on the CK þ CD45 -phenotype.
Conclusion
In conclusion, HER2 þ CTCs can be detected using the LiquidBiopsy system. Among the patients with histologically HER2 þ breast cancer, 41.9% had ! 1 HER2 þ CTC/4 mL of blood. The cell lines experiments showed high sensitivity (100%) and specificity (99.9%) using a HER2/CD45 fluorescence ratio of 3.5.
Clinical Practice Points
Many previous studies of CTCs are based on the CellSearch platform, but CellSearch has a number of limitations. HER2 þ CTCs were detected at all stages, even in early breast cancer, but the frequency was higher in metastatic breast cancer. The results indicated that the LiquidBiopsy system may be useful for detecting HER2 expression as the results were associated with the HER2 status by pathologic examination.
